Economist says NICE should approve fewer costly drugsBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39265.337813.DB (Published 05 July 2007) Cite this as: BMJ 2007;335:11
- Adrian O'Dowd
A leading economist has recommended that the body that determines which drugs can be prescribed by the NHS in England and Wales should change its threshold, so that fewer expensive drugs are approved.
MPs on the health select committee heard from health economists last week as part of their inquiry into various aspects of the National Institute for Health and Clinical Excellence (NICE), including why its decisions and evaluation process are increasingly being challenged.
Peter Smith, director of the Centre for Health Economics, at the University of York, told MPs that NICE's current cost effectiveness threshold was between £20 000 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial